Sequent Scientific announces licensing agreement with Gilead Sciences, Inc for new Hepatitis C drug

- Gilead to license technology to manufacture APIs sofosbuvir and ledipasvir
- Agreement to cover 91 development countries

Bangalore, September 15, 2014: SeQuent Scientific Limited (BSE: 512529) today announced that Gilead Sciences, Inc. has licensed SeQuent to produce active pharmaceutical ingredients (APIs) sofosbuvir and ledipasvir for treatment of chronic hepatitis C.

Under the agreement, SeQuent will receive a complete technology pack from Gilead to enable scale up production of the APIs as quickly as possible. The formulations using these APIs can be distributed in 91 developing countries, which account for more than 100 million people living with hepatitis C, globally representing 54% of the total global infected population.

Sofosbuvir was approved under the trade name Sovaldi® by the U.S. Food and Drug Administration (FDA) in December 2013 and by the European Commission in January 2014. The FDA and the European Medicines Agency are currently reviewing Gilead's applications for a single tablet regimen of ledipasvir/sofosbuvir; it is an investigational agent and its safety and efficacy have not been established

About SeQuent Scientific Limited

SeQuent Scientific Limited, listed on the Bombay Stock Exchange Limited (stock code: 512529) is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services and CRAMS. SeQuent is the world's largest producer of Anthelmintics. Please visit www.sequent.in for additional information.

For additional information, please contact

Manish Gupta, CEO manish@sequent.in Tel: +91 22 41114714	Mr. Rohit Yagnik, Fortuna PR +91 98338 07272; rohit@fortunapr.in